Cutaneous T‐cell pseudolymphoma successfully treated with topical delgocitinib

International Journal of DermatologyEarly View Clinical Correspondence Cutaneous T-cell pseudolymphoma successfully treated with topical delgocitinib Daichi Hoshina, Corresponding Author Daichi Hoshina [email protected] orcid.org/0000-0002-6347-1788 Department of Dermatology, Otaru General Hospital, Otaru, Japan Correspondence Daichi Hoshina Otaru General Hospital Wakamatsu 1-1-1 Otaru 047-8550 Japan E-mail: [email protected]Search for more papers by this authorAyame Kimura, Ayame Kimura Department of Dermatology, Otaru General Hospital, Otaru, JapanSearch for more papers by this author Daichi Hoshina, Corresponding Author Daichi Hoshina [email protected] orcid.org/0000-0002-6347-1788 Department of Dermatology, Otaru General Hospital, Otaru, Japan Correspondence Daichi Hoshina Otaru General Hospital Wakamatsu 1-1-1 Otaru 047-8550 Japan E-mail: [email protected]Search for more papers by this authorAyame Kimura, Ayame Kimura Department of Dermatology, Otaru General Hospital, Otaru, JapanSearch for more papers by this author First published: 14 May 2024 https://doi.org/10.1111/ijd.17239 Conflict of Interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Etesami I, Kalantari Y, Tavakolpour S, Mahmoudi H, Daneshpazhooh M. Drug-induced cutaneous pseudolymphoma: a systematic review of the literature. Australas J Dermatol. 2023; 64: 41–49. 10.1111/ajd.13951 PubMedWeb of Science®Google Scholar 2Surmanowicz P, Doherty S, Sivanand A, Parvinnejad N, Deschenes J, Schneider M, et al. The clinical spectrum of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder: an updated systematic literature review and case series. Dermatology. 2021; 237: 618–628. 10.1159/000511473 CASPubMedWeb of Science®Google Scholar 3Miñarro ÁMG, Juan-Carpena G, Paz LT, Belinchón I, Niveiro M, Salvador JFS. Multiple cutaneous T-cell pseudolymphomas induced by acrylates on patch testing: a case report. Contact Dermatitis. 2023; 88: 166–168. 10.1111/cod.14247 CASPubMedWeb of Science®Google Scholar 4Nakashima C, Yanaghihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022; 71: 40–46. 10.1016/j.alit.2021.10.004 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation